3-(3,5-二氟苯基)丙酰氯 | 95333-92-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(3,5-二氟苯基)丙酰氯
• 英文名称: 3-(3,5-difluorophenyl)propionyl chloride
• 英文别名: 3-(3,5-difluorophenyl)propanoyl chloride；3,5-difluorophenylhydrocinnamoyl chloride
• CAS: 95333-92-9
• 化学式: C₉H₇ClF₂O
• 分子量: 204.604
• InChiKey: OKNUQRZHKPYVPJ-UHFFFAOYSA-N

物化性质

• 沸点：
  234.5±30.0 °C(Predicted)
• 密度：
  1.314±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(3,5-二氟苯基)丙酰氯 在 盐酸 、 lithium aluminium tetrahydride 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 18.0h， 生成 1-[3-(3,5-difluorophenyl)propyl]imidazole-2-thione
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site

  摘要：

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.

  DOI：

  10.1021/jm00386a008
• 作为产物：
  描述：

  1-溴-3,5-二氟苯 在 palladium on activated charcoal 、 镍 哌啶 、 吡啶 、 甲酸 、 氯化亚砜 、 氢气 作用下， 以 四氢呋喃 、 N,N-二甲基乙酰胺 、 N,N-二甲基甲酰胺 为溶剂， 60.0~155.0 ℃ 、344.73 kPa 条件下， 反应 17.0h， 生成 3-(3,5-二氟苯基)丙酰氯
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site

  摘要：

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.

  DOI：

  10.1021/jm00386a008

文献信息

• Novel gamma-lactams as beta-secretase inhibitors
  申请人：Thompson A. Lorin

  公开号：US20060046984A1

  公开（公告）日：2006-03-02

  There is provided a series of novel substituted gamma-lactams of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 4 , R 5 and R 6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列新型取代的γ-内酰胺，化学式为(I)或其立体异构体；或其药用盐，其中R1、R2、R4、R5和R6如本文所定义，它们的药用组合物和使用方法。这些新型化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地抑制Aβ肽的产生。本公开涉及对β-淀粉样蛋白产生相关的神经系统疾病的治疗有用的化合物，如阿尔茨海默病和其他受抗淀粉样活性影响的疾病。
• One-Step Double Covalent Functionalization of Reduced Graphene Oxide with Xanthates and Peroxides
  作者：Florence Pennetreau、Olivier Riant、Sophie Hermans

  DOI：10.1002/chem.201405148

  日期：2014.11.10

  Radical functionalization of reduced graphene oxide has been achieved by reaction with a xanthate in the presence of peroxide as a radical initiator. X‐ray photoelectron spectroscopy, bulk elemental analyses, and thermogravimetric analyses showed that the xanthate grafting is covalent and efficient. The synthesis and use of seven xanthates and three peroxides showed that the highest grafting yield

  通过在过氧化物作为自由基引发剂的存在下与黄原酸酯反应已经实现了还原的氧化石墨烯的自由基官能化。X射线光电子能谱，大量元素分析和热重分析表明，黄原酸酯接枝是共价且有效的。七个黄药和三种过氧化物的合成和使用表明，当以化学计量的量引入黄药和过氧化物时，可获得最高的接枝率。还揭示了在官能化过程中，用作自由基引发剂的过氧化物接枝在石墨表面上。因此，本贡献中提供的方法可以在一个步骤中轻松获得双功能还原氧化石墨烯样品。该方法导致未损坏的石墨烯片比原始样品具有更高的分散性。
• Indanylidenes. 1. Design and Synthesis of (<i>E</i>)-2-(4,6-Difluoro-1-indanylidene)acetamide, a Potent, Centrally Acting Muscle Relaxant with Antiinflammatory and Analgesic Activity
  作者：David L. Musso、Felicia R. Cochran、James L. Kelley、Ed W. McLean、Jeffrey L. Selph、Greg C. Rigdon、G. Faye Orr、Ronda G. Davis、Barrett R. Cooper、Virgil L. Styles、James B. Thompson、William R. Hall

  DOI：10.1021/jm020067s

  日期：2003.1.1

  (E)-N-cyclopropyl-3-(3-fluorophenyl)but-2-enamide, has led to the discovery of the potent, centrally acting muscle relaxant (E)-2-(4,6-difluoro-1-indanylidene)acetamide, 17. Compound 17 also possesses potent antiinflammatory and analgesic activity. This paper describes the synthesis and the muscle relaxant, antiinflammatory, and analgesic structure-activity relationships of 17 and 67 of its analogues

  衍生自肉桂酰胺1，（E）-N-环丙基-3-（3-氟苯基）丙-2-烯酰胺和β-甲基肉桂酰胺2，（E）-N-环丙基-3-（3）的刚性环状类似物的设计-氟苯基）丁-2-烯酰胺已导致发现有效的中枢性肌肉松弛剂（E）-2-（4,6-二氟-1-茚二亚基）乙酰胺17。化合物17还具有有效的抗炎和抗炎作用。镇痛作用。本文描述了17和67类似物的合成及其肌肉松弛，抗炎和止痛结构-活性的关系。化合物17已进入I期临床试验。
• Substituted Tetrahydroisoquinolines as Beta-secretase Inhibitors
  申请人：Thompson Lorin A.

  公开号：US20080153868A1

  公开（公告）日：2008-06-26

  There is provided a series of tetrahydroisoquinoline diaminopropane compounds of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R, R 8 and R 9 are as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供一系列Formula (I)的四氢异喹啉二氨基丙烷化合物或其立体异构体；或其药学上可接受的盐，其中R，R8和R9如本文所定义，它们的药物组合物和使用方法。这些化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地说，抑制Aβ肽的产生。本公开涉及用于治疗与β-淀粉样蛋白产生相关的神经系统疾病的化合物，如阿尔茨海默病和其他受抗淀粉样活性影响的疾病。
• Sulfide Analogues of Flupirtine and Retigabine with Nanomolar K _V 7.2/K _V 7.3 Channel Opening Activity
  作者：Christian Bock、Abdrrahman S. Surur、Kristin Beirow、Markus K. Kindermann、Lukas Schulig、Anja Bodtke、Patrick J. Bednarski、Andreas Link

  DOI：10.1002/cmdc.201900112

  日期：2019.5.6

  Sulfide analogues were identified that are devoid of the risk of quinone formation, but possess potent KV 7.2/3 opening activity. For example, flupirtine analogue 3-(3,5-difluorophenyl)-N-(6-(isobutylthio)-2-(pyrrolidin-1-yl)pyridin-3-yl)propanamide (48) has 100-fold enhanced activity (EC50 =1.4 nm), a vastly improved toxicity/activity ratio, and the same efficacy as retigabine in vitro.

  钾通道开放剂氟吡汀和瑞替加滨已被证明是有价值的镇痛药或抗癫痫药。它们最近分别由于偶发的肝毒性和组织变色而退出治疗，这使得治疗领域没有被填补。两种药物的代谢氧化都会导致亲电子醌的形成。在长期摄入瑞替加滨后发生氟吡汀和蓝色组织变色的情况下，这些难以捉摸的，高反应性的代谢物可能引起肝损伤。我们研究了可以改变哪些结构特征，以避免芳香环的有害氧化，并使氧化向更良性代谢物的形成转移。进行了结构活性关系研究，以评估45种衍生物的KV 7.2 / 3通道开放活性。鉴定出硫化物类似物没有形成醌的风险，但具有有效的KV 7.2 / 3打开活性。例如，氟吡汀类似物3-（3,5-二氟苯基）-N-（6-（异丁硫基）-2-（吡咯烷-1-基）吡啶-3-基）丙酰胺（48）具有100倍的增强活性（ EC50 = 1.4 nm），大大提高了毒性/活性比，并具有与体外瑞替加滨相同的功效。